1. Immunology/Inflammation
  2. Interleukin Related
  3. Tagraxofusp

Tagraxofusp  (Synonyms: SL-401)

Cat. No.: HY-P99536

Tagraxofusp (SL-401) is a potent IL-3 receptor inhibitor to inhibits plasmacytoid dendritic cells (pDCs) growth in multiple myeloma (MM) bone marrow (BM) microenvironment. Tagraxofusp has synergistic effect with Bortezomib (HY-10227) and Pomalidomide (HY-10984) to suppress multiple myeloma (MM).

For research use only. We do not sell to patients.

CAS No. : 2055491-00-2

Size Stock
1 mg Get quote
5 mg Get quote

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Tagraxofusp (SL-401) is a potent IL-3 receptor inhibitor to inhibits plasmacytoid dendritic cells (pDCs) growth in multiple myeloma (MM) bone marrow (BM) microenvironment. Tagraxofusp has synergistic effect with Bortezomib (HY-10227) and Pomalidomide (HY-10984) to suppress multiple myeloma (MM)[1].

Species

Human

IC50 & Target[1]

IL-3

 

In Vitro

Tagraxofusp (0-1367 pM; 72 h) inhibits pDCs viability, as well as pDC-induced proliferation of MM cells. Tagraxofusp (0-136.7 pM; 2-3 weeks) inhibits osteoclast formation and bone resorption, as well as stabilizes osteoblast formation[1].
Tagraxofusp (0-13.67 nM; 48 h) targets tumor-initiating stem-like cells in MM[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: Cancer stem-like cells in MM
Concentration: 0 nM, 0.013 nM, 0.13 nM, 1.3 nM, 13.67 nM
Incubation Time: 48 hours
Result: Inhibits cancer stem-like cells with s of 30 pM (pDCs), 50 nM (MM-SP-Oct4 cells), 75 pM (RPMI-8226-Oct4 cells), 350 pM (MM-SP cells), and 1367 pM (RPMI-8226 cells), respectively.
In Vivo

Tagraxofusp (12-50 μg/kg; i.v.; 5 times per week for 3 weeks) blocks pDC-induced tumor growth and prolongs SCID-hu mice survival in subcutaneous INA-6 MM xenograft model[1].
Tagraxofusp (16 μg/kg; i.v.; 5 times per week for 1 weeks) enhances the anti-MM activity of 2.5 mg/kg Pomalidomide in CB-17 mice of subcutaneous MM xenograft model[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: SCID-hu mice with INA-6 MM cells[1]
Dosage: 12 μg/kg, 16 μg/kg, 25 μg/kg and 50 μg/kg
Administration: Intravenous injection; for 5 consecutive days each week for 3 weeks
Result: Blocked pDC-induced tumor growth and prolonged mice survival at 12 μg/kg.
Showed well tolerance at 16 μg/kg, while higher doses resulted in body weight decrease and toxicity.
Animal Model: CB-17 mice with subcutaneous MM xenograft model[1]
Dosage: 16 μg/kg; with or without 2.5 mg/kg Pomalidomide (p.o.; 4 consecutive days weekly for 2 weeks)
Administration: Intravenous injection; dose at 5 consecutive days for first week
Result: Enhanced the anti-MM activity of proteasome inhibitor and immunomodulatory drug pomalidomide.
Clinical Trial
CAS No.
SMILES

[Tagraxofusp]

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Format
  • Corynebacterium diphtheriae toxin (Pr1,26-411)-IL3 (interleukin 3, interleukin 3 (colony-stimulating factor, multiple))
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Tagraxofusp
Cat. No.:
HY-P99536
Quantity:
MCE Japan Authorized Agent: